Laminar Pharmaceuticals

Laminar Pharmaceuticals, founded in 2006 as a spin-off from the University of the Balearic Islands, is developing a novel class of drugs based on its proprietary Membrane Lipid Therapy (MELItherapy) platform. Its lead asset, LAM561 (idroxioleic acid/2-hydroxyoleic acid), is in a pivotal Phase 2b/3 trial (CLINGLIO) for newly diagnosed glioblastoma, with other programs targeting neurodegenerative and rare diseases. The company is privately held, pre-revenue, and is currently seeking a new capital round to advance its clinical pipeline.

Membrane Lipid Therapy (MELItherapy): A novel therapeutic approach using small molecules to modulate the lipid composition and structure of cell membranes to correct aberrant cell signaling, instead of targeting proteins or DNA directly.

In glioblastoma, LAM561 competes with other novel mechanisms (e.g., tumor treating fields, immunotherapies) and standard chemoradiation, but its lipid-targeting approach is unique. In the broader neurodegeneration space, it faces immense competition from large pharma and biotech, though its membrane-centric mechanism differentiates it from most amyloid, tau, or neuroinflammation-focused therapies.